Syndecan Interactions in Lung Injury and Repair
Syndecan 在肺损伤和修复中的相互作用
基本信息
- 批准号:8259421
- 负责人:
- 金额:$ 43.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2015-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Lung InjuryAdult Respiratory Distress SyndromeAnimal ModelApplications GrantsAttenuatedBindingBiologyCXCL1 geneCell surfaceComplexDataDevelopmentDiseaseDisease ProgressionEndogenous FactorsEndotoxic ShockEnvironmentEpithelialFailureFamilyFoundationsFunctional disorderGlycosaminoglycansGoalsGrantHealedHeparan Sulfate ProteoglycanHeparitin SulfateHost Defense MechanismInfectionInflammationInflammation MediatorsInflammatoryInflammatory ResponseInfusion proceduresKnockout MiceLeadLigand BindingLigandsLigationLungLung InflammationLung diseasesMetalloproteasesModificationMolecularMolecular TargetMorbidity - disease rateMusNeutrophil InfiltrationPatientsPhasePuncture procedureResolutionRoleSepsisSourceT-LymphocyteTestingTherapeuticTimeLineTissuesToxic Shock SyndromeWild Type Mouseattenuationbasedesignextracellularhealingimprovedkillingslung injurylung repairmortalitynovel therapeutic interventionpublic health relevanceresponse to injurysepticsyndecan
项目摘要
DESCRIPTION (provided by applicant): The central goal of this proposal is to define how syndecan interactions modulate lung injury responses in systemic inflammatory diseases. Dysregulated lung injury responses to systemic inflammatory diseases, such as sepsis, can lead to acute lung injury (ALI) and are a major cause of morbidity and mortality. However, many patients survive the initial phase of lung injury and do not progress to ALI or to the more severe form of ALI, acute respiratory distress syndrome (ARDS). These data suggest the importance of endogenous protective mechanisms that attenuate or reverse disease progression, but the underlying biology remains to be elucidated. Syndecans comprise a major family of cell surface heparan sulfate proteoglycans (HSPGs). Syndecans function as coreceptors on the cell surface and also as soluble HSPGs in the extracelular environment because its ectodomain can be shed under inflammatory conditions. Syndecans bind to ligands through its heparan sulfate (HS) chains, a glycosaminoglycan that binds to and regulates several inflammatory mediators implicated in lung injury. However, the precise role of syndecan interactions in inflammatory lung injury has yet to be determined. Syndecan-1 null mice show increased lung injury and mortality when subjected to animal models of systemic inflammatory diseases, such as endotoxic shock, Gram-positive toxic shock, or sepsis. Syndecan-1 shedding is induced in the lungs of wild type mice by the systemic inflammatory challenge, and inhibition of shedding exacerbates lung injury, whereas administration of purified syndecan-1 ectodomain or HS improves disease parameters. Based on these data, this proposal will examine the overall hypothesis that syndecan-1 modulates, in part, the highly complex mechanisms of lung injury and repair in systemic inflammatory diseases in 3 Specific Aims. Aim 1 wil define how syndecan-1 facilitates the resolution of lung inflammation. Aim 2 will determine how syndecan-1 attenuates lung injury and inflammation in sepsis. Aim 3 will establish that temporal syndecan-1 interactions regulate its shedding at the cell surface. These studies should define the key functions of syndecans in lung injury and repair, and provide a mechanistic foundation for the design and development of new therapeutic approaches against inflammatory lung diseases.
PUBLIC HEALTH RELEVANCE: Correctly coordinated inflammation protects from infection and helps heal tissues. However, excessive and inappropriate inflammation can damage tissues and lead to serious complications associated with high morbidity and mortality, such as lung injury, dysfunction, and failure. This grant application will investigate how one of our own molecules called syndecan corrects the dysregulated inflammatory response in the lung, with the goal of identifying new molecular targets for the effective therapeutic control of inflammatory lung diseases.
描述(由申请人提供):该提案的核心目标是定义Syndecan相互作用如何调节全身性炎症性疾病中的肺损伤反应。肺部炎症性疾病(如脓毒症)的肺损伤反应失调可能导致急性肺损伤(ALI),并且是发病率和死亡率的主要原因。但是,许多患者在肺损伤的初始阶段幸存,并且不会发展为ALI或更严重的ALI急性呼吸窘迫综合征(ARDS)。这些数据表明,内源性保护机制减弱或逆转疾病进展的重要性,但潜在的生物学仍有待阐明。 Syndecans包括一个主要的细胞表面硫酸乙酰肝素蛋白聚糖(HSPGS)家族。 syndecan在细胞表面上充当圆锥体的圆锥体,在细胞外环境中也充当可溶性HSPG,因为它的外生域可以在炎症条件下脱落。 Syndecans通过其乙酰肝素(HS)链与配体结合,这是一种糖胺聚糖,与肺损伤有关的几种炎症介质结合并调节。但是,尚未确定syndecan相互作用在炎症性肺损伤中的确切作用。 Syndecan-1 NULL小鼠在遭受全身性炎症性疾病的动物模型(例如内毒素休克,革兰氏阳性毒性休克或败血症)时表现出增加的肺损伤和死亡率。通过全身性炎症挑战诱导Syndecan-1脱落在野生型小鼠的肺中,并抑制脱落加剧肺损伤,而纯化的syndecan-1 ectodopobain或HS给药可改善疾病参数。基于这些数据,该提案将研究总体假设,即Syndecan-1部分调节了3个特定目标中全身性炎症性疾病的高度复杂机制和修复的高度复杂机制。 AIM 1 WIL定义Syndecan-1如何促进肺部炎症的分辨率。 AIM 2将确定Syndecan-1如何减轻败血症的肺损伤和炎症。 AIM 3将确定颞syndecan-1相互作用调节其在细胞表面的脱落。这些研究应定义辛多人在肺损伤和修复中的关键功能,并为针对炎症性肺部疾病的新治疗方法设计和开发提供了机械基础。
公共卫生相关性:正确协调的炎症可防止感染并帮助治愈组织。但是,过度和不当炎症会损害组织,并导致与高发病率和死亡率相关的严重并发症,例如肺损伤,功能障碍和失败。该赠款的应用将调查我们自己的一个称为Syndecan的分子之一如何纠正肺部失调的炎症反应,目的是确定有效控制炎症性肺部疾病的新分子靶标。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Pyong Woo Park其他文献
Pyong Woo Park的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Pyong Woo Park', 18)}}的其他基金
Subversion of Syndecan-1 Functions in Listeriosis
Syndecan-1 在李斯特菌病中的功能被破坏
- 批准号:
10318671 - 财政年份:2020
- 资助金额:
$ 43.5万 - 项目类别:
Syndecan Regulation of Sepsis Host Defense
Syndecan 对脓毒症宿主防御的调节
- 批准号:
10191013 - 财政年份:2018
- 资助金额:
$ 43.5万 - 项目类别:
Syndecan Regulation of Sepsis Host Defense
Syndecan 对脓毒症宿主防御的调节
- 批准号:
9759980 - 财政年份:2018
- 资助金额:
$ 43.5万 - 项目类别:
HSPGs in Alpha-toxin-induced Tissue Injury
HSPG 在α-毒素引起的组织损伤中的作用
- 批准号:
9280796 - 财政年份:2016
- 资助金额:
$ 43.5万 - 项目类别:
Syndecan Interactions in Lung Injury and Repair
Syndecan 在肺损伤和修复中的相互作用
- 批准号:
8086196 - 财政年份:2011
- 资助金额:
$ 43.5万 - 项目类别:
相似国自然基金
ACSS2介导的乙酰辅酶a合成在巨噬细胞组蛋白乙酰化及急性肺损伤发病中的作用机制研究
- 批准号:82370084
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
CDK4/6抑制下调衰老中性粒细胞促炎效应改善急性肺损伤的机制和干预研究
- 批准号:82302445
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于肺间充质干细胞源外泌体lncRNA表达谱差异探讨益气活血解毒法改善脓毒症急性肺损伤的机制
- 批准号:82374400
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
基于巨噬细胞炎性小体活化探究木犀草素治疗急性肺损伤的新机制
- 批准号:82374186
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
DUSP2介导自噬调控气管上皮细胞炎症在急性肺损伤中的机制研究
- 批准号:82360379
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
相似海外基金
Patient Ventilator Asynchrony in Critically Ill Children
危重儿童患者呼吸机异步
- 批准号:
10657157 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Red blood cell ATP export and transfusion in sepsis
脓毒症中红细胞 ATP 输出和输血
- 批准号:
10584768 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
1/2: PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI)
1/2:精确通气以减轻通气引起的肺损伤(预防 VILI)
- 批准号:
10738958 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
2/2: PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI)
2/2:精确通气以减轻通气引起的肺损伤(预防 VILI)
- 批准号:
10738959 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别:
Muscle and physical function recovery after acute critical illness
急性危重病后肌肉和身体机能的恢复
- 批准号:
10584022 - 财政年份:2023
- 资助金额:
$ 43.5万 - 项目类别: